Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...
After hours: March 21 at 7:13:50 PM EDT Loading Chart for VRTX ...
Some standard modules for making 3d shapes with attachment support, and function forms that produce a VNF. Also included are shortcuts cylinders in each orientation and extended versions of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback